TY - JOUR
T1 - Acute cerebrovascular disease following COVID-19
T2 - a single center, retrospective, observational study
AU - Li, Yanan
AU - Li, Man
AU - Wang, Mengdie
AU - Zhou, Yifan
AU - Chang, Jiang
AU - Xian, Ying
AU - Wang, David
AU - Mao, Ling
AU - Jin, Huijuan
AU - Hu, Bo
N1 - Funding Information:
1Department of Neurology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 2Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 3Duke Clinical Research Institute and Department of Neurology, Duke University Medical Center, Durham, North Carolina, USA 4Neurovascular Division, Department of Neurology, Barrow Neurological Institute/ Saint Joseph Hospital Medical Center, Phoenix, Arizona, USA Contributors Concept and design: BH, YL; acquisition, analysis or interpretation of data: JC, HJ, ML, MW, YZ, YX; drafting of the manuscript: BH, YL, ML, HJ, MW, JC, YZ, YX; critical revision of the manuscript for important intellectual content: BH; statistical analysis: JC, YL; obtained funding: BH; administrative, technical or material support: BH, YL, HJ, ML, MW, YZ, YX; supervision: BH. Funding This study was funded by the National Key Research and Development Program of China (number 2018YFC1312200 to BH) and the National Natural Science Foundation of China (number 81820108010 to BH). Competing interests None declared. Patient consent for publication Not required. Provenance and peer review Not commissioned; externally peer reviewed.
Publisher Copyright:
© Author(s) (or their employer(s)) 2020.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background and purpose COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Apart from respiratory complications, acute cerebrovascular disease (CVD) has been observed in some patients with COVID-19. Therefore, we described the clinical characteristics, laboratory features, treatment and outcomes of CVD complicating SARS-CoV-2 infection. Materials and methods Demographic and clinical characteristics, laboratory findings, treatments and clinical outcomes were collected and analysed. Clinical characteristics and laboratory findings of patients with COVID-19 with or without new-onset CVD were compared. Results Of 219 patients with COVID-19, 10 (4.6%) developed acute ischaemic stroke and 1 (0.5%) had intracerebral haemorrhage. COVID-19 with new onset of CVD were significantly older (75.7±10.8 years vs 52.1±15.3 years, p<0.001), more likely to present with severe COVID-19 (81.8% vs 39.9%, p<0.01) and were more likely to have cardiovascular risk factors, including hypertension, diabetes and medical history of CVD (all p<0.05). In addition, they were more likely to have increased inflammatory response and hypercoagulable state as reflected in C reactive protein (51.1 (1.3-127.9) vs 12.1 (0.1-212.0) mg/L, p<0.05) and D-dimer (6.9 (0.3-20.0) vs 0.5 (0.1-20.0) mg/L, p<0.001). Of 10 patients with ischemic stroke; 6 received antiplatelet treatment with aspirin or clopidogrel; and 3 of them died. The other four patients received anticoagulant treatment with enoxaparin and 2 of them died. As of 24 March 2020, six patients with CVD died (54.5%). Conclusion Acute CVD is not uncommon in COVID-19. Our findings suggest that older patients with risk factors are more likely to develop CVD. The development of CVD is an important negative prognostic factor which requires further study to identify optimal management strategy to combat the COVID-19 outbreak.
AB - Background and purpose COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Apart from respiratory complications, acute cerebrovascular disease (CVD) has been observed in some patients with COVID-19. Therefore, we described the clinical characteristics, laboratory features, treatment and outcomes of CVD complicating SARS-CoV-2 infection. Materials and methods Demographic and clinical characteristics, laboratory findings, treatments and clinical outcomes were collected and analysed. Clinical characteristics and laboratory findings of patients with COVID-19 with or without new-onset CVD were compared. Results Of 219 patients with COVID-19, 10 (4.6%) developed acute ischaemic stroke and 1 (0.5%) had intracerebral haemorrhage. COVID-19 with new onset of CVD were significantly older (75.7±10.8 years vs 52.1±15.3 years, p<0.001), more likely to present with severe COVID-19 (81.8% vs 39.9%, p<0.01) and were more likely to have cardiovascular risk factors, including hypertension, diabetes and medical history of CVD (all p<0.05). In addition, they were more likely to have increased inflammatory response and hypercoagulable state as reflected in C reactive protein (51.1 (1.3-127.9) vs 12.1 (0.1-212.0) mg/L, p<0.05) and D-dimer (6.9 (0.3-20.0) vs 0.5 (0.1-20.0) mg/L, p<0.001). Of 10 patients with ischemic stroke; 6 received antiplatelet treatment with aspirin or clopidogrel; and 3 of them died. The other four patients received anticoagulant treatment with enoxaparin and 2 of them died. As of 24 March 2020, six patients with CVD died (54.5%). Conclusion Acute CVD is not uncommon in COVID-19. Our findings suggest that older patients with risk factors are more likely to develop CVD. The development of CVD is an important negative prognostic factor which requires further study to identify optimal management strategy to combat the COVID-19 outbreak.
KW - Anticoagulation therapy
KW - COVID-19
KW - Cerebrovascular disease
KW - Thromboembolic events
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85088259863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088259863&partnerID=8YFLogxK
U2 - 10.1136/svn-2020-000431
DO - 10.1136/svn-2020-000431
M3 - Article
C2 - 32616524
AN - SCOPUS:85088259863
SN - 2059-8688
VL - 5
SP - 279
EP - 284
JO - Stroke and Vascular Neurology
JF - Stroke and Vascular Neurology
IS - 3
M1 - 000431
ER -